Pravastatin activates platelet nitric oxide synthase (NOS) in patients with type 2 diabetes mellitus and NOS activation is accompanied by serine phosphorylation  

作　　者：YAO Kang XU Biao Gao Ling GE Jun-bo 

机构地区：[1]Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital,Fudan University, Shanghai 200032, China [2]Department of Cardiovascular Disease, Gulou Hospital, NanjingUniversity, Nanjing 210008, China

出　　处：《Chinese Medical Journal》2005年第19期1654-1657,共4页中华医学杂志（英文版）

摘　　要：Statins cause reductions in myocardial infarction and also morbidity and mortality of type 2diabetes related to atheromatous disease and its thrombotic complications beyond those predicted by reductions in low density lipoprotein cholesterol （LDL） It has been suggested that the protective mechanism （s） may relate to improved endothelial function and/or antithrombotic effects, but the mechanism is not clear.Statins cause reductions in myocardial infarction and also morbidity and mortality of type 2diabetes related to atheromatous disease and its thrombotic complications beyond those predicted by reductions in low density lipoprotein cholesterol （LDL） It has been suggested that the protective mechanism （s） may relate to improved endothelial function and/or antithrombotic effects, but the mechanism is not clear.

关 键 词：PLATELET HMG-CoA reductase inhibitors type 2 diabetes mellitus nitric oxide synthase 

分 类 号：R587.1[医药卫生—内分泌]